摘要
【摘 要】 目的：分析肺结核伴咯血者以酚妥拉明、垂体后叶素配合治疗的有效性。方法：以 2018.5～ 2020.3期间 100例肺结核伴咯血为研究对象，所有患者均给予常规治疗，同时按治疗小组不同分组，对照组共 48例（采用垂体后叶素）、观察组 52例（酚妥拉明 +垂体后叶素），观察不同用药临床疗效差异，比较两组止血时间、咯血量，统计治疗期间用药所致不良反应。结果：观察组治疗率为 94.2%高于对照组 85.4%， P<0.05;两组止血情况，观察组止血用时短于对照组，咯血量少于对照组， P<0.05;两组不良反应情况比较，观察组发生率为 11.5%低于对照组 25.0%， P<0.05。结论：肺结核咯血者以酚妥拉明、垂体后叶素配合治疗，临床疗效理想，患者咯血症状改善快、咯血量少，且用药不良反应少，可推广应用。
【关键词】 咯血 ;垂体后叶素 ;疗效 ;肺结核 ;酚妥拉明
Objective: to analyze the efficacy of phentolamine and pituitrin in the treatment of pulmonary tuberculosis with hemoptysis. Methods: 100 cases of pulmonary tuberculosis with hemoptysis from May 2018 to March 2020 were selected as the research objects. All patients were given conventional treatment. At the same time, according to the different treatment groups, 48 cases in the control group (pituitrin) and 52 cases (phentolamine + pituitrin) in the observation group. The clinical efficacy differences of different drugs were observed. The hemostatic time and hemoptysis volume of the two groups were compared, and the medication during the treatment was counted Adverse reactions were caused. Results: the treatment rate of the observation group was 94.2%, which was higher than 85.4% of the control group, P < 0.05; the hemostasis time of the observation group was shorter than that of the control group, and the hemoptysis volume was less than that of the control group, P < 0.05; the incidence of adverse reactions in the observation group was 11.5%, lower than that in the control group 25.0%, P < 0.05. Conclusion: the clinical effect of phentolamine and pituitrin in the treatment of pulmonary tuberculosis hemoptysis is ideal. The symptoms of hemoptysis are improved quickly, the amount of hemoptysis is less, and the adverse reaction of medication is less, which can be popularized and applied.
出版日期
2020年09月12日（中国期刊网平台首次上网日期，不代表论文的发表时间）
